Vensana Capital Discloses 9.9% Stake in SpyGlass Pharma Post-IPO, Including Director Nielsen

summarizeSummary

Vensana Capital, an early investor, filed an initial Schedule 13D disclosing a 9.9% beneficial ownership in SpyGlass Pharma following its recent IPO, with Director Kirk Nielsen also reporting beneficial ownership through the fund.

check_boxKey Events

• Initial 13D Filing Post-IPO

  Vensana Capital I, L.P., Vensana Capital I GP, LLC, and their managing directors Kirk Nielsen (a board member) and Peter Justin Klein, filed their initial Schedule 13D.

• Significant Ownership Stake

  The reporting group beneficially owns 3,310,619 shares, representing 9.9% of SpyGlass Pharma's common stock outstanding after the recent initial public offering.

• IPO Participation and Conversion

  Vensana I purchased 165,000 shares of common stock in the IPO for $2.64 million, and its previously held preferred stock automatically converted into common stock upon the IPO's closing on February 9, 2026.

• Lock-Up Agreement in Place

  Vensana I has entered into a standard 180-day lock-up agreement, restricting the sale or transfer of its shares following the IPO.

auto_awesomeAnalysis

This initial Schedule 13D filing provides crucial transparency into SpyGlass Pharma's post-IPO ownership structure, revealing a substantial 9.9% stake held by Vensana Capital and its managing directors, including board member Kirk Nielsen. This disclosure confirms significant institutional backing from a venture capital firm that has been an early investor in the company. The participation in the IPO and the standard lock-up agreement signal continued commitment and a long-term investment horizon, which can be viewed positively by the market for a newly public company.